The use of sunitinib in renal cell carcinoma: where are we now?

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   Google Scholar
• Chae EJ, Kim JK, Kim SH, et al. Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 2005;234(1):189-96
   PubMedGoogle Scholar
• Khan MI, Czarnecka AM, Duchnowska R, et al. Metastasis-initiating cells in renal cancer. Curr Signal Transduct Ther 2013;8:240-6
   Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335(12):865-75
   PubMed Web of Science ®Google Scholar
• Oya M. Renal cell carcinoma: biological features and rationale for molecular-targeted therapy. Keio J Med 2009;58(1):1-11
   PubMedGoogle Scholar
• Czarnecka AM, Kornakiewicz A, Kukwa W, Szczylik C. Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. Future Oncol 2014;10(6):1095-111
   PubMedGoogle Scholar
• Schmidinger M, Arnold D, Szczylik C, et al. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2011;28(8):856-64
   Web of Science ®Google Scholar
• Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011;22(4):794-800
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Eisen T, Szczylik C, et al. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int 2011;107(8):1190-9
   PubMed Web of Science ®Google Scholar
• Arai E, Ushijima S, Tsuda H, et al. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin Cancer Res 2008;14(17):5531-9
   PubMed Web of Science ®Google Scholar
• Ami Y, Shimazui T, Akaza H, et al. Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells. Oncol Rep 2005;13(1):75-80
   PubMedGoogle Scholar
• Czarnecka AM, Szczylik C. Renal cell carcinoma cancer stem cells as therapeutic targets. Curr Signal Transduct Ther 2013;8:203-9
   Google Scholar
• Buczek M, Escudier B, Bartnik E, et al. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient’s bed to molecular mechanisms. Biochim Biophys Acta 2014;1845(1):31-41
   PubMed Web of Science ®Google Scholar
• Bielecka ZF, Czarnecka AM, Solarek W, et al. Mechanisms of acquired resistance to tyrosine kinase inhibitors in clear-cell renal cell carcinoma (ccRCC). Curr Signal Transduct Ther 2013;8:219-28
   Google Scholar
• Brugarolas J. Renal-cell carcinoma – molecular pathways and therapies. N Engl J Med 2007;356(2):185-7
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287-96
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2012;378(9807):1931-9
   Web of Science ®Google Scholar
• Gore ME, Bellmunt J, Eisen T, et al. Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND Corporation/University of California, Los Angeles methodology. Eur J Cancer 2012;48(7):1038-47
   PubMed Web of Science ®Google Scholar
• Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit Rev Oncol Hematol 2012;82(3):323-37
   PubMed Web of Science ®Google Scholar
• Porta C, Bellmunt J, Eisen T, et al. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev 2012;36(1):16-23
   Web of Science ®Google Scholar
• Purmonen TT. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Rev Pharmacoecon Outcomes Res 2011;11(4):383-93
   PubMed Web of Science ®Google Scholar
• Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health 2010;13(6):837-45
   PubMed Web of Science ®Google Scholar
• Ravasio R, Ortega C, Sabbatini R, Porta C. Bevacizumab plus interferon-alpha versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin Drug Investig 2011;31(7):507-17
   PubMedGoogle Scholar
• Benedict A, Figlin RA, Sandstrom P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int 2011;108(5):665-72
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
   PubMed Web of Science ®Google Scholar
• Suarez C, Rini BI. Determining the optimal dose and schedule of sunitinib: some answers, more questions. Cancer 2012;118(5):1178-80
   PubMedGoogle Scholar
• Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46(7):1116-19
   PubMed Web of Science ®Google Scholar
• Patyna S, Laird AD, Mendel DB, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5(7):1774-82
   PubMed Web of Science ®Google Scholar
• Huang D, Ding Y, Li Y, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010;70(3):1053-62
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;69(6):2506-13
   PubMed Web of Science ®Google Scholar
• Hillman GG, Singh-Gupta V, Zhang H, et al. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia 2009;11(9):910-20
   PubMedGoogle Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
   PubMed Web of Science ®Google Scholar
• Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7(3):225-33
   PubMedGoogle Scholar
• Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 2005;96(3):286-90
   PubMedGoogle Scholar
• Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23(5):1028-43
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2(10):1011-21
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
   PubMed Web of Science ®Google Scholar
• Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 2007;3(2):341-8
   PubMedGoogle Scholar
• Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009;15(7):2497-506
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9(15):5465-76
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105(3):986-93
   PubMed Web of Science ®Google Scholar
• Sakamoto KM. Su-11248 Sugen. Curr Opin Investig Drugs 2004;5(12):1329-39
   PubMedGoogle Scholar
• Motzer RJ, Rini BI, Michaelson MD, et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc Am Soc Clin Oncol 2004;22(14): suppl 4500
   Google Scholar
• Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00054886
   Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00077974
   Google Scholar
• Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii65-71
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00903175
   Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31(Suppl):Abstract 4504
   Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00083889
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 2012;9(6):327-37
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722-31
   PubMed Web of Science ®Google Scholar
• Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(25):4068-75
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v137-9
   PubMedGoogle Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT01108445
   Google Scholar
• Armstrong AJ, Halabi S, Eisen T, et al. ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma. J Clin Oncol 2013;31(Suppl):Abstract TPS4590
   Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00979966
   Google Scholar
• Lee JL, Ahn JH, Lim HY, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012;23(8):2108-14
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127-31
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20(9):2376-81
   PubMed Web of Science ®Google Scholar
• Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011;117(3):501-9
   PubMed Web of Science ®Google Scholar
• Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10(8):757-63
   PubMed Web of Science ®Google Scholar
• Strumberg D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J Clin Oncol 2008;26(20):3469-71
   PubMedGoogle Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00130897
   Google Scholar
• Zolnierek J, Nurzynski P, Langiewicz P, et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 2011;136(3):371-8
   Web of Science ®Google Scholar
• Harrison MR, George DJ, Walker MS, et al. “Real world” treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. Clin Genitourin Cancer 2013;11(4):441-50
   PubMedGoogle Scholar
• Sun M, Shariat SF, Trinh QD, et al. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther Adv Urol 2013;5(2):121-8
   PubMedGoogle Scholar
• Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
   PubMed Web of Science ®Google Scholar
• Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13(13):3765-70
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010;36(5):416-24
   PubMed Web of Science ®Google Scholar
• Schwandt A, Wood LS, Rini B, Dreicer R. Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2009;2:51-61
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00720941
   Google Scholar
• Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310. J Clin Oncol 2012;30(Suppl):Abstract CRA4502
   Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT01064310
   Google Scholar
• Vrdoljak E, Ciuleanu T, Kharkevich G, et al. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region. Expert Opin Pharmacother 2012;13(2):159-74
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59(4):526-40
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370(9604):2011-19
   PubMed Web of Science ®Google Scholar
• Neri B, Vannini A, Brugia M, et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol 2013;20(5):478-83
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Bergler-Klein J. Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. Int J Urol 2012;19(9):796-804
   PubMed Web of Science ®Google Scholar
• Kappers MH, van Esch JH, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56(4):675-81
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13(10):1084-96
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Soulieres D, Wong R, et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1(2 Suppl):S41-54
   PubMed Web of Science ®Google Scholar
• Szmit S, Langiewicz P, Zlnierek J, et al. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney Blood Press Res 2012;35(1):18-25
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103(9):763-73
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008;112(11):2500-8
   PubMed Web of Science ®Google Scholar
• Greineder CF, Kohnstamm S, Ky B. Heart failure associated with sunitinib: lessons learned from animal models. Curr Hypertens Rep 2011;13(6):436-41
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Bjarnason G, Burnett P, et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 2011;16(5):543-53
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99(1):81-3
   PubMedGoogle Scholar
• Rogiers A, Wolter P, Op de Beeck K, et al. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 2010;20(3):317-22
   PubMedGoogle Scholar
• Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008;69(4):669-72
   PubMed Web of Science ®Google Scholar
• Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17(4):351-5
   PubMedGoogle Scholar
• Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011;117(3):534-44
   PubMed Web of Science ®Google Scholar
• Baldazzi V, Tassi R, Lapini A, et al. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 2012;30(5):704-10
   PubMed Web of Science ®Google Scholar
• Porta C, Ganini C, Paglino C. Modifying sunitinib schedule in advanced kidney cancer patients: reflections from the results of the renal EFFECT trial. Transl Androl Urol 2012;1(2):120-2
   PubMedGoogle Scholar
• van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99(2):259-65
   PubMedGoogle Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT01499121
   Google Scholar
• Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104(2):93-113
   PubMed Web of Science ®Google Scholar
• Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011;16(Suppl 2):32-44
   PubMed Web of Science ®Google Scholar
• Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008;61(3):515-24
   PubMed Web of Science ®Google Scholar
• Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66(2):357-71
   PubMed Web of Science ®Google Scholar
• Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes in patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014;191(3):611-18
   PubMed Web of Science ®Google Scholar
• Najjar YG, Elson P, Wood LS, et al. Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. J Clin Oncol 2013;31(Suppl 6):Abstract 406
   Google Scholar
• Nozawa M, Uemura H. Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma. Transl Androl Urol 2012;1(4):202-3
   PubMedGoogle Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00267748
   Google Scholar
• Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30(12):1371-7
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Oborska S, Rzepecki P, Szczylik C. Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. Future Oncol 2014. [Epub ahead of print]
   Google Scholar
• Maroto P, Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res 2014;20(8):2060-71
   PubMed Web of Science ®Google Scholar
• Mlot B, Szczylik C, Rzepecki P. Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - apoptosis-regulating factors. Contemp Oncol (Pozn) 2012;16(1):90-3
   PubMedGoogle Scholar
• Mlot B, Szczylik C, Rzepecki P. Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors. Contemp Oncol (Pozn) 2012;16(3):250-3
   PubMedGoogle Scholar
• Michel MS, Vervenne W, de Santis M, et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). J Clin Oncol 2014;32(Suppl 4):Abstract 393
   Web of Science ®Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT01219751
   Google Scholar
• Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012;30(1):335-40
   PubMed Web of Science ®Google Scholar
• Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012;62(6):1013-19
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. Available from: http://clinicaltrials.gov/show/NCT00465179?displayxml=true
   Google Scholar
• Flaig TW, Kim FJ, La Rosa FG, et al. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 2009;27(1):83-7
   PubMedGoogle Scholar
• Gilabert M, Provansal M, Cappiello M, et al. Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma. Br J Cancer 2013;109(7):1750-4
   PubMedGoogle Scholar
• Sevin A, Chen A, Atkinson B. Tyrosine kinase inhibitor induced pancreatitis. J Oncol Pharm Pract 2013;19(3):257-60
   PubMedGoogle Scholar
• Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 2009;3(3):170-9
   PubMedGoogle Scholar
• Choi YA, Sim EH, Lee KE, et al. [A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma]. Korean J Gastroenterol 2013;61(6):347-50
   PubMedGoogle Scholar
• Hoshino Y, Hasegawa H, Ishii Y, et al. Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. Int J Clin Oncol 2012;17(4):412-16
   PubMedGoogle Scholar
• Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011;10(3):151-6
   PubMed Web of Science ®Google Scholar
• Poprach A, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012;23(12):3137-43
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161(5):1045-51
   PubMed Web of Science ®Google Scholar
• Rini BI, Choueiri TK, Elson P, et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008;113(6):1309-14
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Oborska S, Rzepecki P, Szczylik C. Development of CML in the course of ccRCC treatment with tyrosine kinase inhibitors – clinical report with molecular model. BJU Int 2013;112(Suppl 3):1-17
   Google Scholar
• Winn SK, Ellis S, Savage P, et al. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009;24(2):673-5
   PubMedGoogle Scholar
• Katta A, Fesler MJ, Tan A, et al. Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy. Cancer Chemother Pharmacol 2010;66(2):409-12
   PubMedGoogle Scholar
• Costero O, Picazo ML, Zamora P, et al. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 2010;25(3):1001-3
   PubMedGoogle Scholar
• Talebi TN, Stefanovic A, Merchan J, et al. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. Am J Ther 2012;19(4):e143-5
   Google Scholar
• Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 2007;369(9577):1923-4
   PubMed Web of Science ®Google Scholar